Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Diagnosis of AD according to the American Academy of Dermatology consensus criteria (Eichenfield 2003) at screening visit~2. Chronic AD diagnosed at least 1 year prior to the screening visit~3. IGA = 4 at screening and baseline visits~4. EASI ≥21 at the screening and baseline visits~5. BSA ≥15% at screening and baseline visits~6. Documented recent history (within 6 months before the baseline visit) of inadequate response to topical AD medication(s)~7. At least 11 (of a total of 14) applications of a stable dose of topical emollient (moisturizer) twice daily during the 7 consecutive days immediately before the baseline visit~Key Exclusion Criteria:~1. Participation in a prior dupilumab clinical study~2. Treatment with a systemic investigational drug before the baseline visit~3. Treatment with a topical investigational drug within 2 weeks prior to the baseline visit~4. Treatment with crisabarole within 2 weeks prior to the baseline visit~5. History of important side effects of medium potency topical corticosteroids (e.g, intolerance to treatment, hypersensitivity reactions, significant skin atrophy, systemic effects), as assessed by the investigator or patient's treating physician~6. Treatment with a topical calcineurin inhibitor (TCI) within 2 weeks prior to the baseline visit~7. Having used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during the first 4 weeks of study treatment:~   1. Immunosuppressive/immunomodulating drugs (e.g, systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon gamma, Janus kinase inhibitors, azathioprine, methotrexate, etc.)~  2. Phototherapy for AD~8. Treatment with biologics, as follows:~   1. Any cell-depleting agents including but not limited to rituximab:~      within 6 months before the baseline visit, or until lymphocyte and CD 19+ lymphocyte count returns to normal, whichever is longer~  2. Other biologics: within 5 half-lives (if known) or 16 weeks before the baseline visit, whichever is longer~9. Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit~10. Body weight \<15 kg at baseline~Note: Other Inclusion/ Exclusion criteria apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Participants will receive dupilumab, dosing regimen 1
- Group 2 (Type: EXPERIMENTAL): Participants will receive dupilumab, dosing regimen 2
- Group 3 (Type: EXPERIMENTAL): Participants will receive matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete